Thus the peptide binding sites of MAGE-A3 and MAGE-A4 may be important for MAGE regulation in vivo, and drug molecules targeting these sites could potentially lock the MHD in the “closed” conformation, prevent binding to their RING domain partners, and antagonize their proliferative and survival activities in cancer cells. The gene discussed is MAGEA4; the disease is cancer.